Polo-like kinase 1 inhibitor BI6727 sensitizes 9L gliosarcoma cells to ionizing irradiation by Li, Nan et al.
University of Wollongong 
Research Online 
Faculty of Engineering and Information 
Sciences - Papers: Part B 
Faculty of Engineering and Information 
Sciences 
2019 
Polo-like kinase 1 inhibitor BI6727 sensitizes 9L gliosarcoma cells to 
ionizing irradiation 
Nan Li 
University of Wollongong, nli@uow.edu.au 
Elette Engels 
University of Wollongong, ee215@uowmail.edu.au 
Jeremy A. Davis 
University of Wollongong, jeremyd@uow.edu.au 
Andrew Dipuglia 
University of Wollongong, ad150@uowmail.edu.au 
Sarah Vogel 
University of Wollongong, sv855@uowmail.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/eispapers1 
 Part of the Engineering Commons, and the Science and Technology Studies Commons 
Recommended Citation 
Li, Nan; Engels, Elette; Davis, Jeremy A.; Dipuglia, Andrew; Vogel, Sarah; Valceski, Michael; Rosenfeld, 
Anatoly B.; Lerch, Michael L. F; Corde, Stephanie; and Tehei, Moeava, "Polo-like kinase 1 inhibitor BI6727 
sensitizes 9L gliosarcoma cells to ionizing irradiation" (2019). Faculty of Engineering and Information 
Sciences - Papers: Part B. 3347. 
https://ro.uow.edu.au/eispapers1/3347 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Polo-like kinase 1 inhibitor BI6727 sensitizes 9L gliosarcoma cells to ionizing 
irradiation 
Abstract 
Surgery, chemotherapy and radiotherapy remain as the major treatment strategies for cancers. Some 
agents such as anti-cancer drugs have capacity to enhance the radiation sensitivity of cancer cells at G2/
M phase, leading to an improved radiotherapeutic efficacy. BI6727 is an ATP-competitive pololike kinase 1 
(Plk 1)inhibitor and an anti-cancer drug. Using the radio-resistant 9L rat gliosarcoma cells as model, we 
examined the effect of BI6727 on cell growth and assessed the chemoradiotherapeutic efficiency 
between 150 kVp conventional irradiation (dose rate of 0.76 Gy min−1 ) and 66 keV synchrotron x-ray 
broad beam irradiation (dose rate of 46 Gy s−1). Our studies showed that BI6727 significantly caused cell 
growth arrest at G2/M phase and inhibited 9L cell proliferation with EC50 of 58.1 nM. In combinatory 
treatment, irradiation of BI6727-treated 9L cells with synchrotron x-rays at a dose rate of 46 Gy s−1 
resulted in significant reduction of the cell survival compared to the conventional x-rays at a dose rate of 
0.76 Gy min−1. These results indicated that Plk1 inhibitor BI6727 enhanced radio-sensitization of 9L cells 
in a dose rate dependent manner. For clinical application, irradiation with high dose rate is a promising 
strategy to improve chemo-radiotherapeutic efficacy for gliosarcoma cancer. 
Keywords 
gliosarcoma, 9l, sensitizes, bi6727, inhibitor, 1, irradiation, kinase, ionizing, polo-like, cells 
Disciplines 
Engineering | Science and Technology Studies 
Publication Details 
Li, N., Engels, E., Davis, J. A., Dipuglia, A., Vogel, S., Valceski, M., Rosenfeld, A. B., Lerch, M. L. F., Corde, S. & 
Tehei, M. (2019). Polo-like kinase 1 inhibitor BI6727 sensitizes 9L gliosarcoma cells to ionizing irradiation. 
Biomedical Physics & Engineering Express, 5 067003-1-067003-9. 
Authors 
Nan Li, Elette Engels, Jeremy A. Davis, Andrew Dipuglia, Sarah Vogel, Michael Valceski, Anatoly B. 
Rosenfeld, Michael L. F Lerch, Stephanie Corde, and Moeava Tehei 
This journal article is available at Research Online: https://ro.uow.edu.au/eispapers1/3347 
Biomedical Physics & Engineering
Express
     
ACCEPTED MANUSCRIPT
Polo-like kinase 1 inhibitor BI6727 sensitizes 9L gliosarcoma cells to
ionizing irradiation
To cite this article before publication: Nan Li et al 2019 Biomed. Phys. Eng. Express in press https://doi.org/10.1088/2057-1976/ab4d0e
Manuscript version: Accepted Manuscript
Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process,
and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted
Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”
This Accepted Manuscript is © 2019 IOP Publishing Ltd.
 
During the embargo period (the 12 month period from the publication of the Version of Record of this article), the Accepted Manuscript is fully
protected by copyright and cannot be reused or reposted elsewhere.
As the Version of Record of this article is going to be / has been published on a subscription basis, this Accepted Manuscript is available for reuse
under a CC BY-NC-ND 3.0 licence after the 12 month embargo period.
After the embargo period, everyone is permitted to use copy and redistribute this article for non-commercial purposes only, provided that they
adhere to all the terms of the licence https://creativecommons.org/licences/by-nc-nd/3.0
Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content
within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this
article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions will likely be
required. All third party content is fully copyright protected, unless specifically stated otherwise in the figure caption in the Version of Record.
View the article online for updates and enhancements.
This content was downloaded from IP address 203.10.91.74 on 17/10/2019 at 23:39
	 1	
Polo-like kinase 1 inhibitor BI6727 sensitizes 9L gliosarcoma cells to 
ionizing irradiation 
 
Nan Li1,2, Elette Engels1,2, Jeremy A. Davis1,2, Andrew Dipuglia1, Sarah Vogel1,2, Michael 
Valceski1,2, Anatoly B. Rosenfeld1, Michael L. F. Lerch1,2, Stéphanie Corde1,2,3 and Moeava 
Tehei1,2 
1 Centre for Medical Radiation Physics, Wollongong, NSW, Australia  
2. Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia  
3. Radiation Oncology Department, Prince of Wales Hospital, Randwick, NSW, Australia  
 
Corresponding Author: Moeava Tehei, email: moeava@uow.edu.au 
 
Key words: Plk1, BI6727, G2/M arrest, DNA damage, radio-sensitization 
 
 
Abstract 
 
Surgery, chemotherapy and radiotherapy remain as the major treatment strategies for 
cancers. Some agents such as anti-cancer drugs have capacity to enhance the radiation 
sensitivity of cancer cells at G2/M phase, leading to an improved radiotherapeutic 
efficacy. BI6727 is an ATP-competitive polo-like kinase 1 (Plk 1) inhibitor and an anti-
cancer drug. Using the radio-resistant 9L rat gliosarcoma cells as model, we examined 
the effect of BI6727 on cell growth and assessed the chemo-radiotherapeutic efficiency 
between 150 kVp conventional irradiation (dose rate of 0.76 Gy/min) and 66 keV 
synchrotron X-ray broad beam irradiation (dose rate of 46 Gy/sec ). Our studies showed 
that BI6727 significantly caused cell growth arrest at G2/M phase and inhibited 9L cell 
proliferation with EC50 of 58.1 nM.  In combinatory treatment, irradiation of BI6727-
treated 9L cells with synchrotron X-rays at a dose rate of 46 Gy/sec resulted in 
significant reduction of the cell survival compared to the conventional X-rays at a dose 
rate of 0.76 Gy/min. These results indicated that Plk1 inhibitor BI6727 enhanced radio-
sensitization of 9L cells in a dose rate dependent manner. For clinical application, 
irradiation with high dose rate is a promising strategy to improve chemo-
radiotherapeutic efficacy for gliosarcoma cancer. 
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1. Introduction 
 
Brain cancer remains as one of the most aggressive incurable cancer types. Gliosarcoma 
(GSM) is a very rare neoplasm with an incidence of 1-8% of all malignant gliomas [1]. 
GSM has similar epidemiology and natural history to glioblastoma multiforme (GBM), 
the most common primary brain cancer with a median survival of about 15 months [1-
2]. GSM and GBM usually recur despite maximum treatment with less than 3% to 5% 
of survival rate over five years [3]. The overall survival is typically 3 months without 
any treatment [4]. Treatment for brain cancer involves surgery, chemotherapy and 
radiation therapy. However, radio-resistance is common in GBM and GSM [2].  Hence, 
developing methods by involving novel anti-cancer drugs with radio-sensitization 
potential and new radiotherapy modalities would be the path to largely improve the 
radiotherapeutic efficacy.   
 
The anti-cancer drug volasertib (BI6727) is a polo-like kinase 1 (Plk1) inhibitor [5-6].  
Plk1 plays critical roles in eukaryotic cell division by regulating centrosome 
maturation, spindle assembly, microtubule–kinetochore attachment and cytokinesis 
during mitosis [7-8]. Plk1 overexpression in cancer cells correlates with prognosis of 
cancer progression [9]. Inhibition of Plk1 in cancer cells causes G2/M phase arrest, 
mitotic catastrophe and apoptosis [10-11].  It was reported that Plk1 inhibitors inhibited 
cancer cell growth including brain cancer cells and increased their radio-sensitivity [12-
18]. Significant improvement of local tumour control was observed in an in vivo study 
with combinatory treatment of Plk1 inhibition and fractionated irradiation [19].  
 
X-ray dose rate is an important factor that affects biological consequences such as cell 
survival for a given absorbed dose. It was reported that low dose rate with extended 
exposure time would increase cell survival comparing to high dose rate [20]. Therefore, 
dose rate is a crucial factor in radiotherapy.  
 
In this work, radio-resistant 9L gliosarcoma cell line was used as a model to investigate 
the combinatory effect of BI6727 with low dose-rate conventional and high dose-rate 
synchrotron broad beam irradiation. The 9L cell line is the most widely used 
experimental rat brain tumor model to study the treatment strategies for aggressive 
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brain tumours [21]. Here we reported a newly developed chemo-radiotherapy that 
significantly increased the mortality of radio-resistance brain cancer cells.  
 
2. Methods 
 
2.1. Cell culture 
Rat 9L gliosarcoma cell line was obtained from the European Collection of Cell 
Cultures (ECACC).  Cells were cultured in DMEM with L-Glutamine and high glucose 
(Gibco, Life Technologies) supplemented with 10% fetal bovine serum (Bovogen 
Biologicals) and 1% penicillin/streptomycin (10,000 units/ml) (Gibco, Life 
Technologies). Cell growth was maintained in 37 °C  humidified atmosphere with 95% 
air and 5% CO2.  
 
2.2. Drug treatment with Plk1 inhibitor BI6727  
Plk1 inhibitor BI6727 (Selleckchem) was reconstituted in dimethyl sulfoxide (DMSO) 
according to the manufacturer’s instructions and stored at -80 oC. BI6727 was added to 
cell culture with the final DMSO concentration of 0.1% in the culture. Cells treated 
with DMSO alone were used as vector-treated control.  
 
2.3. Measurement of cell growth by MTT proliferation assay 
9L cells (2000 cells/well) were seeded to 96-well plates and allowed to attach and grow 
at 37 oC for 24 hours prior to BI6727 treatment. Cells were then treated with different 
concentrations of BI6727 for 72 hours. Cell proliferation was determined by MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay using Vybrant® 
MTT Cell Proliferation Assay Kit (Molecular Probes). The plates were read using a 
SpectraMax Plus 384 Microplate Reader at wavelength of 540 nm. Experiments were 
carried out in triplicate and background absorbance was subtracted from all wells before 
analysis. 
 
2.4. Cell cycle analysis by flow cytometry 
9L cells were incubated with BI6727 at 50 nM for 24 hours before being detached from 
T25 flasks (Corning). The collected cells were fixed with 70% ethanol and stained with 
propidium iodide (PI). The stained cells were then analyzed using a Becton Dickinson 
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fluorescence-activated cell sorting (FACS) flow cytometer (BD LSR II; BD 
Biosciences, USA). The data was analysed using BD FACSDiva Software.  
 
2.5. Combination of BI 6727 and ionizing radiation 
9L cells were cultured in Falcon 12.5 cm² cell culture flasks (T12.5 flasks). Cells were 
incubated with 50 nM of BI6727 for 24 hours prior to irradiation. A radiation dose of 
8 Gy was delivered as a single fraction from conventional and synchrotron X-ray 
sources, respectively. 
 
Conventional irradiation on 9L cells at low dose rate was performed in the Radiation 
Oncology Department at the Prince of Wales Hospital (POWH) (Randwick, NSW, 
Australia) with a Nucletron Oldelft Therapax DXT 300 Series 3 Orthovoltage unit 
(Nucletron B.V., Veenendaal, The Netherlands). The tube potential was 150 kVp with 
additional filtration of 0.35 mm Cu and 1.5 mm Al, resulting in a beam of 0.67 mm Cu 
half value layer, with a dose rate of 0.76 Gy/min at 50 cm from the source. The 
irradiation set-up and the photon energy spectrum were described elsewhere [22]. 
Briefly, monolayer confluent cells in flasks were delivered 8 Gy at 6 mm-depth in 
medium in a horizontal orientation with solid water placed around the sides and beneath 
the flasks to maintain a full scatter condition.  
 
Irradiation on 9L cells at high dose rate was conducted at hutch 2B on Imaging and 
Medical Beam Line (IMBL) in the Australian Synchrotron (AS). The flasks with 9L 
cells were filled with Hank's Balanced Salt Solution (HBSS) (Gibco, Life 
Technologies). Each flask was irradiated vertically in a specifically designed solid 
water phantom, the cell monolayers being 2.5 cm downstream. The pink broad beam 
was produced by 2.2 T wiggler field and filtered by Cu-Al filters (without ex-vacuo) 
with mean weighted energy of 66 keV and dose rate of 46 Gy/sec. This beam energy 
was chosen to match as closely as possible the effective energy of the conventional 150 
kVp X-ray source [23]. Therefore, the energy effect would be negligible when 
comparing the radiation effects on cell survival from the two X-ray sources. 
 
2.6. Clonogenic assay 
9L cells were grown in T12.5 flasks for the treatments with/without BI6727 and/or 
irradiation. After the treatment, cells in each flask were re-seeded to Corning Primaria 
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100 mm cell culture dishes as described previously [24]. After 15 doubling times, the 
plates were washed and stained with crystal violet solution. Only colonies with at least 
50 cells were counted as surviving and normalized to the untreated control to calculate 
the surviving fractions [24]. 
 
2.7. Immunofluorescence detection of gH2AX by flow cytometry  
To stop DNA repair during the conventional irradiation in POWH, 9L cells in T12.5 
flasks were irradiated on ice. The cells were then incubated at 37 oC for 1 hour before 
being collected for the assay. H2AX phosphorylation assay kit for flow cytometry 
(Upstate Biotechnology) was used for the detection of cellular gH2AX in response to 
DNA damage with a modified protocol [25]. The FITC-labeled cells were counter 
stained with 10 µg /ml PI. The FITC and PI double labeled cells were analyzed using a 
Becton Dickinson fluorescence-activated cell sorting (FACS) flow cytometer (BD LSR 
II; BD Biosciences, USA). The data was analyzed using BD FACSDiva Software.  
 
2.8. Immunofluorescence detection of gH2AX by fluorescence microscopy  
For immunofluorescence imaging, 50 nM of BI6727 was applied to 9L cells grown in 
T12.5 flasks for 24 hours, followed by conventional irradiation in POWH or 
synchrotron irradiation in AS, as stated in 2.5. For conventional irradiation, 9L cells in 
flasks were irradiated on ice and were incubated for 20 min (37oC 5 min and room 
temperature 15 min) before the cell fixation was performed. While for the synchrotron 
irradiation, the flasks were irradiated at room temperature and then were kept at room 
temperature for 20 min before the cell fixation step. Synchrotron irradiation took less 
than one minute, the DNA repair during irradiation was neglected.  
 
The immunofluorescence staining procedures were performed using the method 
described previously [26]. Mouse anti-gH2AX (Ser139) antibody (Upstate 
Biotechnology, 1:500 dilution) and goat anti-mouse antibody conjugated with Alexa-
488 (Molecular Probes, 1:500 dilution) were applied. gH2AX images were acquired at 
room temperature with a Leica DMI4000B inverted fluorescence microscope with a 
10x objective lens. 
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The gH2AX fluorescence intensity in the images was analyzed using program ImageJ 
[27] and a modified method for counting particles 
(https://microscopy.duke.edu/guides/count-nuclear-foci-ImageJ). In brief, the nucleus 
with gH2AX fluorescence were counted as particles (the white color spots in images). 
Therefore, the number of particles could represent the number of cells with gH2AX 
signals. The ‘analyze particles’ program available in ImageJ was used to count the 
number of particles after an intensity threshold was set (from 0 to 65535 for the 16 bit 
images used). The initial intensity threshold was set low to count all of the particles 
which represented all of the cells in the image (the total particles Nt).  By gradually 
increasing the intensity threshold, the number of counted particles (or cells) were 
recorded as they changed as a function of gH2AX fluorescence intensity. The 
proportion of counted particles which related to the cell population at each threshold 
was normalized as a percentage of the total particle number Nt. The correlation between 
the cell population and gH2AX intensity could be obtained by plotting this serial 
intensity thresholds to the cell populations. The gH2AX intensity in non-irradiated cells 
was considered as background, which was subtracted from the plot for respective 
irradiated cell images.  
 
2.9. Statistical analysis 
Statistical significance was calculated using Student’s unpaired two-tailed t-test. The 
level of statistical significance was chosen as P < 0.05.  Error bars represent the 
standard deviation (SD) of the mean (n ≥ 3). GraphPad Prism 7 was used to calculate 
EC50 values and to compute the nonlinear regression equations. 
 
3. Results 
3.1. Plk 1 inhibitor BI6727 suppressed 9L cell growth by inducing G2/M arrest  
To assess the inhibition of 9L cell growth by BI6727, MTT assay was carried out by 
incubating 9L cells for 72 hours with different concentrations of BI6727 in a range of 
1 nM to 10 µM.  As shown in Figure 1, BI6727 significantly inhibited the proliferation 
of 9L cells with an EC50 of 58.1 nM (Figure 1a).  
 
Page 6 of 18AUTHOR SUBMITTED MANUSCRIPT - BPEX-101661.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 A
cc
ep
te
d 
M
a
us
rip
t
	 7	
Strong G2/M phase arrest was also observed in cells treated with BI6727 at 50 nM for 
24 hours. Cell cycle analysis showed an increased cell population of 51.6% at G2/M 
phases when compared to the vector-treated control (26.7%, figure 1b). Given that cells 
in G2/M phase are more susceptible to irradiation than in other phases [28], 
accumulation of cells in G2/M phase induced by BI6727 would increase the sensitivity 
of cells to applied ionizing irradiation. 
 
		
 
 
Figure 1. Plk1 suppressed the proliferation and colony formation of 9L cells by 
inducing mitotic arrest. a. MTT based proliferation assay. 9L cells were incubated with 
different concentrations of BI6727 for 72 hours.  EC50 was calculated to be 58.1 nM 
using GraphPad. b. BI6727 induced G2/M arrest in 9L cells. 9L cells were incubated 
with 50 nM BI6727 for 24 hours and the cell cycle was analyzed using PI staining and 
flow cytometry. c. Clonogenic assay to assess the intrinsic cytotoxicity of a 24 hours 
exposure of 9L cells to 50 nM BI6727. DMSO-treated cells were used as control. Data 
represents a mean ± SD from three independent experiments.  Bars indicate the standard 
deviation (SD). ****P £  0.0001 
 
3.2. Inhibition of Plk 1 reduced colony-forming ability of 9L cells 
Clonogenic assay was used to assess the cell survival or division capability after drug 
treatment [29]. As indicated in Figure 1c, the survival of 9L cells was reduced 
significantly to 68.0% after 24 hours of treatment with 50 nM BI6727 when compared 
to the control (P £ 0.0001) (Figure 1c).  
 
3.3. Plk1 inhibitor BI6727 enhanced radio-sensitivity of 9L cells in a dose rate 
dependent manner 
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 It is well known that cells at G2/M phase are more sensitive to radiation [28]. To assess 
whether BI6727-induced G2/M arrest in 9L cells could enhance radio-sensitization as 
well as the impact of dose rate on the enhancement, irradiation was carried out using 
two X-ray sources with different dose rates. A dose of 8 Gy to the cells was delivered 
as a single fraction for both irradiations. As indicated in Fig. 2, irradiation with 
synchrotron X-ray source (AS) at a dose rate of 46 Gy/sec led to a high reduction of 
cell surviving fraction compared to the conventional X-ray source at a dose rate of 0.76 
Gy/min (POWH). This occurred for both non-BI6727-treated control (11.2% vs. 
16.0%; P<0.001, columns c and a) and BI6727-treated 9L cells (7.0% vs. 13.4%, 
P<0.0001, columns d and b). For the cells treated with the conventional X-ray source, 
combinatory treatment with BI6727 was able to decrease the surviving ability of 9L 
cells with slight significance (13.4% vs. 16.0%; P<0.05, Fig. 2, columns b and a). 
However, for the cells treated with synchrotron X-ray source, combinatory treatment 
with BI6727 significantly reduced the survival of 9L cells compared to the control with 
irradiation-only (7.0% vs. 11.2%, P<0.001. Fig. 2, columns d and c). These results 
indicated that BI6767 treatment was able to enhance the sensitivity of 9L cells to 
irradiation and the enhanced radio-sensitivity is likely dose rate dependent.  
 
 
		 	 
Figure 2. BI6727 sensitized 9L cells to irradiation. 9L cells were treated with 50 nM 
BI6727 for 24 hours prior to irradiation that was delivered to a dose of 8 Gy in a single 
fraction from two different X-ray sources: POWH (energy 150 kVp, dose rate of 0.76 
Gy/min) and AS (energy 66 keV, dose rates of 46 Gy/sec). The cell survival was 
assessed by clonogenic assay. Column a: control with conventional irradiation only; 
column b: BI6727 in combination with conventional irradiation; columns c: control 
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with synchrotron irradiation only; column d: BI6727 in combination with synchrotron 
irradiation. The surviving fractions were calculated by normalizing to non-irradiated 
vector-treated cells (for columns a and c) or non-irradiated BI6727-treated cells (for 
columns b and d), respectively. Data represents mean ± SD from three independent 
experiments. *P £ 0.05, ***P £ 0.001 and ****P £ 0.0001. 
 
 
3.4. Combinatory treatment significantly induced DNA damage in G2/M arrested cells 
Plk1 plays critical role in mitosis and maintaining the genome stability.   Disruption of 
Plk1 function has a potential to cause DNA damage. Further, irradiation induces more 
DNA damage on G2/M arrested cells. To assess the accumulated effect of DNA damage 
induced by BI6727 and irradiation, we measured gH2AX signals in the non-treated and 
treated cells using flow cytometry and immunofluorescence imaging techniques.  
 
Without BI6727 treatment, the cell populations were largely distributed in G0-G1 
phases and the gH2AX signals induced by ionizing irradiation were mainly assigned to 
these populations (Figure 3a and 3b). BI6727 along can cause DNA damage with weak 
gH2AX intensity (Figure 3c). Upon exposing to irradiation, high gH2AX intensity (in 
purple color) was observed in G2/M phase cells indicating the formation of large 
amount of gH2AX foci in response to double-strand DNA breaks (Figure 3d).   
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Figure 3. Bivariate PI-combined gH2AX analysis by flow cytometry in 9L cells after 
the treatment of BI6727 and x-ray irradiation. (a) vector-treated control; (b) 8 Gy 
irradiation; (c) 50 nM BI6727 for 24 hours; (d) 50 nM BI6727 for 24 hours and 8 Gy 
irradiation.  The 8 Gy irradiation was delivered in a single fraction from POWH 150 
kVp X-ray source. The cells were stained with FITC conjugated anti-phospho-H2AX 
(Ser139) and PI. gH2AX fluorescence detected with different intensity was shown as 
blue (low intensity) and purple (high intensity). The experiment was repeated three 
times. 
 
DNA damage from these treatments was further observed by immunofluorescence 
imaging analysis. As indicated in Figure 4a, more and/or stronger gH2AX foci were 
observed in  cells exposed to the synchrotron irradiation comparing to the conventional 
irradiation treatment.  Further, when analyzing the cell populations vs. gH2AX 
fluorescence intensity, higher gH2AX fluorescence intensity was observed in BI6727-
treated cells exposed to either synchrotron or conventional irradiation (Figure 4b). After 
a threshold pixel intensity above 35000, only the gH2AX signals from BI6727-treated 
cells exposed to synchrotron irradiation remained. This indicated that the combinatory 
treatment of BI6727 and synchrotron irradiation induced higher DNA damage over the 
conventional irradiation in BI6727-treated cells.  
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   Figure 4. Immunofluorescence imaging for gH2AX detection. 9L cells were treated 
with 50 nM BI6727 for 24 hours prior to 8 Gy irradiation from POWH 150 kVp and 
AS 66 keV X-ray sources, respectively. (a) Cellular gH2AX foci (in white) were 
detected by anti-gH2AX (Ser139) primary antibody and Alexa-488 conjugated 
secondary antibody. Images are representatives of three repeats. (b) The comparison of 
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the plots between the cell population and gH2AX intensity for non-BI6727-treated and 
BI6727-treated 9L cells after exposing to conventional and synchrotron 8 Gy 
irradiation. The gH2AX fluorescence images were analyzed using ImageJ. Images were 
collected and analyzed from three repeats. 
 
 
4. Discussion 
 
Plk1 is a potential anti-cancer target due to its overexpression in many cancer cells but 
not in normal tissues. Many Plk1 inhibitors have been developed for cancer intervention 
with a few drugs being currently applied in clinical trials [5-6]. Of these, BI6727, an 
ATP competitive Plk1 inhibitors, inhibits cancer cells significantly at nanomolar 
concentrations and has better pharmacokinetics profile [6].  
 
In our study we firstly characterized the inhibitory ability of BI6727 on 9L cells.  The 
inhibitory effect of BI6727 on 9L is modest with EC50 of 58.1 nM when compared to 
other cell lines treated with BI6727 and similar ATP competitive Plk1 inhibitors 
BI2536 and GSK463416 [15, 30-32].  Cell survival measured by clonogenic assay 
reduced to 68.0% when treated with 50 nM BI6727 for 24 hours, which is comparable 
to the survival of most of the reported brain tumour cell lines treated with 50 nM BI2536 
(the SFs were between 33.6% and 69.7%) [16]. Thus, BI6727 at 50 nM was used in the 
combinatory chemo-irradiation treatment throughout. 
 
Plk1 inhibition induces G2/M arrest and enhances radio-sensitization in many cancer 
cells. In our study, we showed that the Plk1 inhibitor BI6727 remarkably induced cell 
arrest in G2/M phase and increased more sensitivity of the radio-resistant 9L cells to 
high dose-rate synchrotron irradiation than to the low dose-rate conventional 
irradiation. The reduced cell survival after ionizing irradiation is related to DNA 
damage. Indeed, we have observed enhanced stronger gH2AX signals in BI6727-
treated cells exposed to synchrotron irradiation than those exposed to conventional 
irradiation, indicating the increased DNA damage in synchrotron irradiation.  
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9L cell line is well known for its radio-resistance comparing with other rat brain tumour 
cells [33-34]. We previously reported that there was no survival change at given doses 
up to 8 Gy with two different dose rates of 0.5 Gy/min and 5 Gy/min from 10 MV 
irradiation [35]. However, the present study demonstrated a significant dose rate effect 
on the survival of 9L cells at the given dose of 8 Gy with the dose rate increased from 
0.76 Gy/min to 46 Gy/sec. A similar dose rate effect on 9L cell survival was also 
observed in our previous study [36]. In this case, at the given dose of 2 Gy, the cell 
survival was reduced from 74% to 32% when the dose rate increased from 0.76 Gy/min 
to 50 Gy/sec from conventional and synchrotron broad beam irradiation respectively, 
although the beam energy for synchrotron irradiation was 137 keV [36]. Hence, the 
dose rate is critical for inhibitory effect of post-irradiation survival in 9L cells and the 
dose rate effect must be considered for the future in vivo studies when utilising high 
dose-rate irradiation.  
 
Recent studies investigating FLASH radiotherapy have demonstrated that there is a 
significant dose rate dependence between healthy tissue and tumours [37-39]. High 
dose rates (>40 Gy/s) have been shown to increase normal tissue sparing [37] and 
maintain tumour control [38].  A recent animal study demonstrated that ultra-high dose 
rate synchrotron X-rays could also trigger the FLASH effect [40]. In this study, the 
normal brain injury in mice was prevented after a 10 Gy whole brain irradiation (mean 
dose rate 37 Gy/s) [40]. This has pointed out a promising future for our study when we 
extend our current work to preclinical studies using the synchrotron X-ray source.  
  
There is a high demand on development of novel treatment strategies such as new anti-
cancer drugs and new radiotherapy modalities. In addition to the high selectivity and 
inhibitory ability, BI6727 was reported to be able to pass through the blood brain 
barrier, making it a promising anti-brain tumour drug [18]. It is agreeable that more 
work is required on measuring the cell survival and the associated DNA damage and 
repair dynamics for different dose rate irradiation, our current findings provide 
evidence that combing PLK inhibitor with high dose rate irradiation could also become 
a new path in killing strong radio-resistant cancer cells  
 
5. Conclusion 
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Radio-resistance is a major problem for brain tumor radiotherapy. Developing new 
treatment strategy to reduce radio-resistance and thereof to improve therapeutic 
efficiency is beneficial for cancer patients. BI6727 treatment significantly improves the 
sensitivity of 9L cells to irradiation in a dose-rate dependent manner, suggesting an 
efficient treatment strategy for radio-resistant gliosarcoma cancer.  
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